Sofiva Genomics Co., Ltd. (6615) Stock Price & Analysis
6615 Stock Chart & Stats
- Day’s Range
- TWD 31.95 - TWD 32.95
- 52-Week Range
- TWD 28.90 - TWD 40.00
- Previous Close
- TWD 32.95
- Volume
- N/A
- Average Volume (3M)
- 12.89K
- Market Cap
- TWD 708.26M
- Enterprise Value
- TWD 689.31M
- Total Cash (Recent Filing)
- TWD 131.52M
- Total Debt (Recent Filing)
- TWD 38.30M
- Price to Earnings (P/E)
- 49.7
- Beta
- 0.19
- Next Earnings
- Nov 18, 2026 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jun 27, 2025
- Dividend Yield
- 0.91%
6615 FAQ
What was Sofiva Genomics Co., Ltd.’s price range in the past 12 months?
What is Sofiva Genomics Co., Ltd.’s market cap?
When is Sofiva Genomics Co., Ltd.’s upcoming earnings report date?
How were Sofiva Genomics Co., Ltd.’s earnings last quarter?
Is Sofiva Genomics Co., Ltd. overvalued?
Does Sofiva Genomics Co., Ltd. pay dividends?
What is Sofiva Genomics Co., Ltd.’s EPS estimate?
How many shares outstanding does Sofiva Genomics Co., Ltd. have?
What happened to Sofiva Genomics Co., Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sofiva Genomics Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Sofiva Genomics Co., Ltd.
Sofiva Genomics Co.,Ltd., established in 2012 and based in Taipei, Taiwan, offers a comprehensive range of genetic testing services to both domestic and international clients. The company's diverse diagnostic solutions are designed to support expectant parents, individuals with inherited conditions, and their families. Their extensive prenatal diagnostics include screenings for conditions such as thalassemia carrier status, various microdeletion syndromes, single-gene abnormalities, common chromosomal anomalies, and specific skeletal dysplasia mutations. They also provide multi-gene panel testing for inherited diseases, folate metabolism genetic analysis, carrier screening for spinal muscular atrophy (SMA) and Fragile X syndrome, congenital infection detection, preeclampsia risk assessment, maternal serum screening for Down syndrome, and karyotyping. Within the oncology sector, Sofiva Genomics delivers advanced cancer screenings, dynamic monitoring of tumor activity, and genetic evaluations for hereditary cancer predisposition. This includes specialized panels for women's cancers (breast, colon, ovarian, and endometrial), alongside human papillomavirus (HPV) screening. Furthermore, the company conducts genetic testing for rare diseases and provides specialized reproductive services such as preimplantation genetic diagnosis (PGD) and next-generation sequencing (NGS)-based preimplantation genetic screening (PGS). For newborns, their services encompass comprehensive "baby scans," screenings for hereditary sensorineural hearing loss, congenital central hypoventilation syndrome (CCHS), congenital cytomegalovirus (CMV) infection, and genetic risk assessment for atopic dermatitis. Beyond these specialized offerings, Sofiva Genomics also performs biochemical and chromosomal analyses, complemented by valuable advisory and support services for its clientele.
- Sector
- General
- Industry
- Medical - Diagnostics & Research
- CEO
- Chia-Cheng Hung
- Employees
- 15
- Website
- www.sofivagenomics.com.tw
- Address
- No. 27, Baoqing Road, Taipei, TPE, 10043, TW
Sofiva Genomics Co., Ltd. (6615) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 15 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 0 | 0 | 12 |
